Atlas Trials

Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma

Clinical trial NCT02696356 · COMPLETED

Trial details

NCT number
NCT02696356
Sponsor
BrightPath Biotherapeutics
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Melanoma
Start date
2016-04-01
Primary completion
2018-03-01
Enrollment
18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.